Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
1.29
Dollar change
+0.07
Percentage change
5.74
%
Index- P/E- EPS (ttm)-0.58 Insider Own1.36% Shs Outstand173.86M Perf Week4.03%
Market Cap224.28M Forward P/E- EPS next Y-0.39 Insider Trans0.00% Shs Float171.49M Perf Month1.57%
Income-82.47M PEG- EPS next Q-0.14 Inst Own18.03% Short Float9.10% Perf Quarter114.96%
Sales7.38M P/S30.39 EPS this Y20.47% Inst Trans10.09% Short Ratio7.77 Perf Half Y81.69%
Book/sh0.38 P/B3.42 EPS next Y13.24% ROA-67.13% Short Interest15.61M Perf Year69.74%
Cash/sh0.23 P/C5.65 EPS next 5Y- ROE-97.94% 52W Range0.53 - 1.59 Perf YTD125.21%
Dividend Est.- P/FCF- EPS past 5Y27.81% ROI-105.98% 52W High-18.87% Beta0.44
Dividend TTM- Quick Ratio3.32 Sales past 5Y1341.69% Gross Margin37.61% 52W Low143.40% ATR (14)0.09
Dividend Ex-DateNov 09, 2012 Current Ratio3.32 EPS Y/Y TTM31.83% Oper. Margin-1129.52% RSI (14)60.79 Volatility5.73% 7.40%
Employees125 Debt/Eq0.46 Sales Y/Y TTM6796.26% Profit Margin-1117.56% Recom1.00 Target Price5.00
Option/ShortYes / Yes LT Debt/Eq0.35 EPS Q/Q37.29% Payout- Rel Volume0.80 Prev Close1.22
Sales Surprise288.70% EPS Surprise17.48% Sales Q/Q14650.00% EarningsMar 14 AMC Avg Volume2.01M Price1.29
SMA208.40% SMA5015.03% SMA20055.89% Trades Volume1,611,138 Change5.74%
Date Action Analyst Rating Change Price Target Change
Dec-29-21Resumed Jefferies Buy $13 → $12
Nov-02-21Initiated Cantor Fitzgerald Overweight $15
Jun-29-21Downgrade B. Riley Securities Buy → Neutral $13 → $9
Jun-24-21Initiated Jefferies Buy $13
Jun-11-21Initiated Piper Sandler Overweight $18
Aug-12-20Reiterated H.C. Wainwright Buy $7 → $17
Jul-13-20Initiated B. Riley FBR Buy $22
Mar-27-24 08:00AM
Mar-20-24 08:00AM
Mar-15-24 01:45PM
07:33AM
Mar-14-24 08:55PM
05:35PM Loading…
05:35PM
04:01PM
Mar-07-24 08:00AM
Mar-06-24 08:00AM
Feb-26-24 12:00PM
Feb-20-24 09:55AM
Feb-05-24 08:00AM
Jan-19-24 08:30AM
Jan-16-24 09:25AM
09:22AM
08:00AM Loading…
Dec-21-23 08:00AM
Nov-03-23 11:47AM
Nov-02-23 06:39PM
04:01PM
08:00AM
Oct-26-23 08:00AM
Oct-11-23 08:00AM
Sep-21-23 08:00AM
Sep-12-23 12:48PM
Sep-06-23 04:05PM
Aug-15-23 01:46PM
Aug-05-23 06:39AM
Aug-03-23 05:15PM
04:01PM
Jul-27-23 08:00AM
08:00AM Loading…
Jul-06-23 08:00AM
Jun-26-23 04:45PM
Jun-21-23 04:30PM
Jun-07-23 09:16AM
Jun-06-23 04:01PM
08:00AM
May-31-23 08:00AM
07:47AM
May-04-23 04:01PM
Apr-28-23 08:00AM
Apr-24-23 05:30AM
Mar-29-23 08:00AM
Mar-18-23 02:56AM
Mar-17-23 08:00AM
Mar-15-23 04:01PM
Mar-08-23 04:05PM
Feb-14-23 08:00AM
Jan-18-23 09:00AM
Jan-09-23 08:27AM
Dec-19-22 08:00AM
Dec-01-22 08:00AM
Nov-22-22 08:30AM
Nov-11-22 05:47AM
Nov-08-22 05:45PM
04:01PM
Nov-01-22 10:01AM
Oct-25-22 05:06AM
Oct-20-22 08:30AM
Oct-10-22 08:00AM
Oct-04-22 06:20AM
Sep-07-22 08:30AM
Sep-01-22 06:30AM
Aug-31-22 04:30PM
08:30AM
Aug-25-22 04:05PM
Aug-08-22 05:35PM
04:01PM
08:00AM
Aug-05-22 08:00AM
Aug-03-22 07:55AM
Jul-29-22 10:56AM
Jul-28-22 04:05PM
Jul-27-22 08:00AM
Jul-20-22 08:30AM
Jul-14-22 08:00AM
Jul-01-22 09:00AM
Jun-30-22 08:00AM
Jun-29-22 06:00AM
Jun-16-22 04:05PM
Jun-08-22 09:05AM
Jun-07-22 10:30AM
Jun-03-22 08:00AM
Jun-02-22 08:45AM
08:30AM
08:00AM
May-20-22 03:33PM
May-19-22 08:30AM
May-18-22 05:51AM
May-16-22 06:00AM
May-13-22 04:17PM
May-09-22 05:46PM
May-04-22 02:25PM
Apr-27-22 06:30AM
Apr-14-22 08:30AM
06:00AM
Apr-07-22 05:51AM
Apr-06-22 05:21AM
Mar-29-22 10:12AM
Mar-26-22 11:15AM
06:55AM
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.